Additional Listing

23 June 2014

Source BioScience plc("Source BioScience" or "the Company")

Additional Listing on Exercise of Share Options

Source BioScience plc (LSE: SBS) announces that it has issued 125,000 new ordinary shares of2 pence each in the Company ("Ordinary Shares"), following the exercise of options under the Company's 1999 Unapproved Share Option scheme.

An application has been made for the new Ordinary Shares to be admitted to the Official List of the UK Listing Authority and to trading on the Main Market of the London Stock Exchange. Admission of the new Ordinary Shares will occur as soon as reasonably practical.

Following the issue and allotment, the Company's issued share capital will comprise 313,573,965 Ordinary Shares of 2 pence each. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, Source BioScience plc under the FCA's Disclosure and Transparency Rules. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Enquiries

Source BioScience plc

Dr Nick Ash, CEO

Tel: +44 (0) 115 973 9010

Email: enquiries@sourcebioscience.com

www.sourcebioscience.com

For investor enquiries:

N+1 Singer (Financial Advisor and Broker)

Aubrey Powell/James White

Tel: +44 (0)20 7496 3000

www.n1singer.com

About Source BioScience:

Source BioScience is a trusted provider of state-of-the-art products and services to the healthcare and clinical, life and applied scientific and biopharma industries. It is an international business with centres in four countries and customers in over 90 countries. The Group offers a complementary portfolio of products and services that share common technologies, lab processes, infrastructure and expertise. These include clinical diagnostics, genomics, proteomics, drug discovery and development research as well as controlled environment storage and testing services for a diverse range of markets. These products and services are provided to a large and diverse customer base including the top 50 pharmaceutical companies, leading universities and research institutes worldwide, the UK NHS and other healthcare providers. The Group is listed on the Premium Main Market of the London Stock Exchange (LSE: SBS).